Yakult extends Proacta alliance to another anticancer prodrug
This article was originally published in Scrip
Executive Summary
Japan's Yakult Honsha has expanded a collaborative R&D and commercialisation agreement with Proacta to include another of the private US firm's hypoxia-activated prodrugs for cancer.